Get the Stockscreener App
3.39
5.57%
-0.20
Pre-market:
3.25
-0.14
-4.13%
Xenetic Biosciences Inc stock is traded at $3.39, with a volume of 14,252.
It is down -5.57% in the last 24 hours and down -19.19% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
See More
Previous Close:
$3.59
Open:
$3.68
24h Volume:
14,252
Relative Volume:
1.68
Market Cap:
$5.23M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.2327
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
-10.55%
1M Performance:
-19.19%
6M Performance:
-15.05%
1Y Performance:
-18.71%
1-Day Range:
$3.2501
$3.68
1-Week Range:
$3.2501
$3.845
52-Week Range:
$2.78
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.39 | 5.23M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success - StockTitan
Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Milton Daily Standard
Can Xenetic's DNase I Innovation Finally Crack the Solid Tumor Barrier for CAR-T Therapy? - StockTitan
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 21.4% in January - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January - Defense World
Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology - ACCESS Newswire
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com
XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com
XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World
Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan
Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan
Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK
Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada
Xenetic and PeriNess partner for cancer treatment trials - Investing.com
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire
Xenetic Biosciences (STU:3XB0) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 43.2% in November - Defense World
HC Wainwright Reiterates Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Bio's DNase I Shows Breakthrough in Colorectal Cancer Treatment Efficacy | XBIO Stock News - StockTitan
XBIOXenetic Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire
Xenetic Bio's DNase I + CAR T Cell Therapy Shows Breakthrough in Melanoma Treatment | XBIO Stock News - StockTitan
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks
Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan
Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):